
    
      Secondary objectives:

        -  patients with virologic response ratio at 48 weeks (less than 50 plasma viral load)

        -  Change in the number of CD4 cells at 48 weeks

        -  Change in body composition and mineral density bone (body and lumbar) measurement with
           DEXA (bone mineral density scan) at 48 weeks

        -  Change in markers of renal function (creatinine clearance, glomerular filtration rate -
           eGFR - estimated rate) and renal tubular function at 48 weeks

        -  Rate of mortality and clinical progression at 48 weeks

        -  general tolerability and safety: adverse events (AA) and serious AA description
    
  